Chlamydia vaccine moves a step closer

By | August 13, 2019

Researchers found the vaccine provoked an immune response during preliminary tests on 35 healthy women.

Further trials will be carried out to determine whether it can fully protect against the infection, but experts say it is an “important first step” in tackling the condition.

“The findings are encouraging as they show the vaccine is safe and produces the type of immune response that could potentially protect against chlamydia,” said Professor Robin Shattock, from Imperial College London.

“The next step is to take the vaccine forward to further trials, but until that’s done, we won’t know whether it is truly protective or not.”

Chlamydia is the most common bacterial STI in the world, with young adults the most affected.

It can lead to infertility, as well as complications such as ectopic pregnancy, arthritis and increased susceptibility to other STIs such as HIV.

The infection is currently treated with antibiotics, but people can still catch it again. As many as three quarters of cases show no symptoms.

The study, led by Imperial College London and the Statens Serum Institut in Copenhagen, tested two different formulations of the vaccine to examine which would perform better.

Both formulations provoked an immune response in 100 per cent of participants – compared to no immune response in those given a placebo – but one was found to perform better and produce more antibodies.

The experts hope this formulation will undergo further clinical development.

The research, published in the journal The Lancet Infectious Diseases, found the vaccines produced no serious adverse reactions.

Australian Associated Press

Western Advocate – Health